Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
284lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
3 lessons
7mResearchAdvanced
MOTS-c's 503A Recommendation: What Changed and What Did Not
MOTS-c now has a favorable advisory recommendation. It still does not have FDA drug approval or an open 503A compounding path.
8mResearchAdvanced
BPC-157 and GLP-1 Side Effects: What the Research Really Shows
GLP-1 receptor agonists cause nausea in up to 44% of users and it is the top reason for discontinuation. Here is what the research shows about BPC-157 as a potential gut protectant, and where the evidence stops.
8mResearchAdvanced
Tirzepatide vs. Semaglutide: What the 2026 Data Actually Shows
New head-to-head trials and real-world data from 2025-2026 reveal tirzepatide and semaglutide are not equivalent - they produce meaningfully different outcomes depending on your goals.
Also available at /blog for legacy links.